NCT03887780View on ClinicalTrials.gov

A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)

CompletedOBSERVATIONAL
Enrollment

504

Participants

Timeline

Start Date

October 3, 2019

Primary Completion Date

December 23, 2023

Study Completion Date

December 16, 2024

Conditions
Non-valvular Atrial Fibrillation (NVAF)
Interventions
DRUG

Rivaroxaban (Xarelto,Bay 59-7939)

15 mg and 20 mg (OD)

Trial Locations (1)

500003

Sunshine Hospital, Secunderabad

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY

NCT03887780 - A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF) | Biotech Hunter | Biotech Hunter